Q3 EPS Estimates for Arcus Biosciences Reduced by Wedbush

Key Points

• Wedbush has reduced its Q3 2025 earnings per share (EPS) estimate for Arcus Biosciences from ($1.13) to ($1.35), maintaining an "Outperform" rating with a price target of $33.00.
• Several brokerages have lowered their price targets on Arcus Biosciences, with Barclays cutting their target from $29.00 to $14.00 and Goldman Sachs reducing theirs from $15.00 to $13.00.
• Institutional investors have increased their stakes in Arcus Biosciences, with Gilead Sciences acquiring a new position worth approximately $447.6 million in the company.

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Wedbush decreased their Q3 2025 earnings per share (EPS) estimates for shares of Arcus Biosciences in a note issued to investors on Thursday, August 7th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($1.35) per share for the quarter, down from their previous forecast of ($1.13). Wedbush has a "Outperform" rating and a $33.00 price objective on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences' Q4 2025 earnings at ($1.37) EPS, FY2025 earnings at ($3.85) EPS, Q1 2026 earnings at ($1.38) EPS, Q2 2026 earnings at ($1.36) EPS, Q3 2026 earnings at ($1.08) EPS, Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($4.85) EPS, FY2027 earnings at ($3.66) EPS and FY2028 earnings at ($0.73) EPS.

A number of other equities analysts have also recently commented on the company. Morgan Stanley lowered their target price on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a report on Friday, May 9th. The Goldman Sachs Group lowered their target price on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Wells Fargo & Company lowered their target price on Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Wall Street Zen upgraded Arcus Biosciences from a "strong sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Barclays lowered their target price on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Arcus Biosciences has an average rating of "Moderate Buy" and a consensus target price of $21.14.

Arcus Biosciences Trading Down 1.8%

Shares of NYSE RCUS traded down $0.18 during mid-day trading on Monday, reaching $9.88. 251,334 shares of the company's stock were exchanged, compared to its average volume of 1,031,702. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -3.11 and a beta of 0.89. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.50 and a current ratio of 4.50. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $18.98. The company's 50-day moving average is $9.15 and its 200-day moving average is $9.39.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.03. The company had revenue of $160.00 million during the quarter, compared to analysts' expectations of $32.86 million. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%. The firm's quarterly revenue was up 310.3% on a year-over-year basis. During the same period in the prior year, the business earned ($1.02) EPS.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Gilead Sciences Inc. boosted its stake in shares of Arcus Biosciences by 4.5% in the 1st quarter. Gilead Sciences Inc. now owns 31,424,760 shares of the company's stock valued at $246,684,000 after buying an additional 1,363,636 shares during the period. Vanguard Group Inc. boosted its stake in shares of Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock valued at $52,499,000 after buying an additional 1,298,584 shares during the period. Woodline Partners LP raised its position in shares of Arcus Biosciences by 45.5% during the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company's stock worth $40,249,000 after acquiring an additional 1,603,367 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Arcus Biosciences by 11.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company's stock worth $25,348,000 after acquiring an additional 178,351 shares in the last quarter. Finally, Boxer Capital Management LLC acquired a new stake in shares of Arcus Biosciences during the 4th quarter worth about $23,857,000. Hedge funds and other institutional investors own 92.89% of the company's stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.